Information about blood cancer

In this section you will find disease specific information on the main types of blood cancers and allied blood disorders.

Blood Cancer Information

In this section you will find disease specific information on the main types of blood cancers and allied blood disorders.

Living well with Leukaemia

It's important to look after yourself, your body and your mind following a diagnosis of a blood cancer.

I’ve just been diagnosed with blood cancer or leukaemia

You may have just learnt you have leukaemia and be wondering about all the things you need to consider following such a life-changing diagnosis. Don't worry, we're here to support you.

Clinical trials

Learning about cancer and cancer treatment is a continuous process. Every new idea and development in treatment needs to be tested in a way that is scientifically reliable. This is done by testing the treatments in controlled trials.

COVID-19 information hub

Find all the latest COVID-19 information from FAQs to patient experiences as well as advice from our team.

Podcasts

Leukaemia Chatters from Leukaemia Care is the latest launch from the team to ensure that you can get the information you need

Blood Cancer Awareness Month

Awareness of blood cancers like leukaemia need to be dramatically improved. Help to raise awareness of the signs and symptoms of leukaemia this Blood Cancer Awareness Month and beyond.

Read More

Take a Moment to Catch Up

View our latest news and blog articles

April 23rd

Cost of leukaemia – Tony Pullen on sick pay

Tony Pullen talks openly about how being diagnosed with hairy cell leukaemia (HCL) has impacted his financial stability. ...

April 11th

Approval for the first CAR-T treatment for ALL is renewed

CAR-T therapy, tisagenlecleucel, has been given long term approval to be used on the NHS in England, thanks to a decision made by the National Institute for Health and Care Excellence's (NICE). ...

March 11th

NEW oral treatment for AML patients approved in Scotland

Leukaemia Care are pleased to announce that newly diagnosed acute myeloid leukaemia (AML) patient with an IDH1 mutation who are ineligible for standard induction chemotherapy now have access to ivosidenib with azacitidine thanks to the decision made by the Scottish Medicines Consortium (SMC) today....